Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma
Journal article published in 2013 by
L. Calafiore,
L. Amoroso,
O. Della Casa Alberighi,
R. Luksch,
G. Zanazzo,
A. Castellano,
M. Podda 
,
Carlo Dominici,
R. Haupt,
M. V. Corrias,
A. Garaventa
,
Carlo Dominici,
R. Haupt,
M. V. Corrias,
A. Garaventa
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Background: Cure rate for subjects with refractory or relapsing metastatic neuroblastoma is